Thomas, L., Cellular and Humoral Aspects of Hypersensitivity States. 1959; New York: Hoeber.
Filipovich A, Malignancies in the Immunocompromised Human. In: Elsevier. 1980; New York: North Holland.
Filipovich, A.H., et al., Lymphoproliferative disorders and other tumors complicating immunodeficiencies. Immunodeficiency, 1994; 5(2): p. 91–112.PubMed
Griener, T.C., K.S. Baker, and T.G. Gross, Posttransplant lymphoproliferative disease in children, ed. A.S.C.O.E. Book. 2004; 596–603.
Smith, M.A. and L.A.G. Ries, Childhood cancer: incidence, survival, and mortality. Principles and practice of pediatric oncology, ed. P. D. Pizzo PA. 1997; Philadelphia: Lippincott-Raven. 1–20.
Sandlund, J.T., Malignant lymphomas in childhood. Hematology basic principles and practices, 3rd ed. 2000; New York: Churchill Livingstone.
Anagnostopoulos, I., et al., Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood, 1995; 85(3): p. 744–50.PubMed
Li, Q.X., et al., Epstein-Barr virus infection and replication in a human epithelial cell system. Nature, 1992; 356(6367): p. 347–50.PubMed
Masucci, M.G. and I. Ernberg, Epstein-Barr virus: adaptation to a life within the immune system. Trends Microbiol, 1994; 2(4): p. 125–30.PubMed
Babcock, G.J., et al., EBV persistence in memory B cells in vivo. Immunity, 1998; 9(3): p. 395–404.PubMed
Yang, J., et al., Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood, 2000; 96(13): p. 4055–63.PubMed
Kieff, E., Epstein Barr viurs and its replication. Field virology. 3rd edn, ed. K. D. Fields BN, Howley PM. 1996; Philadelphia: Lippincott-Raven Publishers. 2343–96.
Brooks, L.A., et al., Transcripts from the Epstein-Barr virus BamHI A fragment are detectable in all three forms of virus latency. J Virol, 1993; 67(6): p. 3182–90.PubMed
Cohen, J.I., Epstein-Barr virus infection. N Engl J Med, 2000; 343(7): p. 481–92.PubMed
Chen, H., et al., Expression of Epstein-Barr virus Bam-HI-A rightward transcripts in latently infected B cells from peripheral blood. Blood, 1999; 93(9): p. 3026–32.PubMed
Yang, J., et al., Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood, 2000; 95(1): p. 241–8.PubMed
Thorley-Lawson, D.A., Basic virological aspects of Epstein-Barr virus infection. Semin Hematol, 1988; 25(3): p. 247–60.PubMed
Tomkinson, B.E., et al., Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol, 1987; 139(11): p. 3802–7.PubMed
Rickinson, A.B. and D.J. Moss, Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol, 1997; 15: p. 405–31.PubMed
Callan, M.F., et al., Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo. J Exp Med, 1998; 187(9): p. 1395–402.PubMed
Tan, L.C., et al., Are-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol, 1999.; 162(3): p. 1827–35.PubMed
Appay, V., et al., Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med, 2002; 8(4): p. 379–85.PubMed
McKenna, R.W., et al., Ultrastructural, cytochemical, and membrane surface marker characteristics of the atypical lymphocytes in infectious mononucleosis. Blood, 1977; 50(3): p. 505–15.PubMed
Silins, S.L., et al., Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood, 2001; 98(13): p. 3739–44.PubMed
Okano, M. and T.G. Gross, Epstein-Barr virus-associated hemophagocytic syndrome and fatal infectious mononucleosis. Am J Hematol, 1996; 53(2): p. 111–5.PubMed
Greiner, T. and T. Gross, Atypical Immune Lymphoproliferations. 4 ed. Hematology Basic Principles and Practice, ed. R. Hoffman, Benz E.J., Shattil S.J., et al. 2005; New York: Elsevier Churchill Livingston. 1561–1574.
Pearson, G., Infectious mononucleosis: The humoral response. 2nd edn. Infectious mononucleosis, ed. I.S. D. 1989; New York: Springer-Verlag. 89–99.
Norwitz CA, H. W., Henle G et al., Longterm serological followup of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis, 1985; 151: p. 1150–3.
Henle, W., G.E. Henle, and C.A. Horwitz, Epstein-Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol, 1974; 5(5): p. 551–65.PubMed
Evans, A.S., et al., A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody. J Infect Dis, 1975; 132(5): p. 546–54.PubMed
Durbin, W.A. and J.L. Sullivan, Epstein-Barr virus infection. Pediatr Rev, 1994; 15(2): p. 63–8; quiz 68.PubMed
Paul, J.R. and W.W. Bunnell, The presence of heterophile antibodies in infectious mononucleosis. Am J Med Sci, 1974; 267(3): p. 178–88.PubMed
Buell, J., Gross TG, Woodle ES, Malignancy after transplantation. Transplantation, 2005; 80: p. S254–64.PubMed
U.S. Renal Data System. USRDS 1998 Annual Data Report. Diseases. 1998; Bethseda, MD: National Institutes of Health.
Howard, R.J., et al., The changing causes of graft loss and death after kidney transplantation. Transplantation, 2002; 73(12): p. 1923–8.PubMed
Abu-Elmagd, K.M., et al., De novo malignancies after intestinal and multivisceral transplantation. Transplantation, 2004; 77(11): p. 1719–25.PubMed
Baker, K.S., et al., New malignancies after blood or marrow stem cell transplantation in children and adults: incidence and risk factors. J Clin Oncol, 2003; 21(7): p. 1352–8.PubMed
Kolb, H.J., et al., Malignant neoplasms in long—term survivors of bone marrow transplantation. Late Effects Working Party of the European Cooperative Group for Blood and Marrow Transplantation and the European Late Effect Project Group. Ann Intern Med, 1999; 131(10): p. 738–44.PubMed
Bustami, R.T., et al., Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant, 2004; 4(1): p. 87–93.PubMed
Harris, N.L., J.A. Ferry, and S.H. Swerdlow, Posttransplant lymphoproliferative disorders: summary of Society or Hematopathology Workshop. Semin Diagnathol, 1997; 14(1): p. 8–14.
Gross, T.G., Low-dose chemotherapy for children with post-transplant lymphoproliferative disease. Recent Results Cancer Res, 2002; 159: p. 96–103.PubMed
Collins, M.H., et al., Autopsy pathology of pediatric posttransplant lymphoproliferative disorder. Pediatrics, 2001; 107(6): p. E89.PubMed
Gross, T.G., et al., B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant, 1999; 23(3): p. 251–8.PubMed
Chadburn, A., et al., Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer, 1995; 75(11): p. 2747–56.PubMed
Capello, D., et al., Molecular histogenesis of posttransplantation lymphoproliferative disorders. Blood, 2003; 102(10): p. 3775–85.PubMed
Gulley, M.L., et al., Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy. Transplantation, 2003; 76(6): p. 959–64.PubMed
Hanson, M.N., et al., Posttransplant T-cell lymphoproliferative disorders — an aggressive, late complication of solid-organ transplantation. Blood, 1996; 88(9): p. 3626–33.PubMed
Rajakariar, R., et al., Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant, 2004; 4(9): p. 1534–8.PubMed
Bierman, P.J., et al., Hodgkin’s disease following solid organ transplantation. Ann Oncol, 1996; 7(3): p. 265–70.PubMed
Ranganathan, S. and R. Jaffe, Is there a difference between Hodgkin’s disease and a Hodgkin’s-like posttransplant lymphoproliferative disorder, and why should that be of any interest? Pediatr Transplant, 2004; 8(1): p. 6–8.PubMed
Childs, C.C., D.M. Parham, and C.W. Berard, Infectious mononucleosis. The spectrum of morphologic changes simulating lymphoma in lymph nodes and tonsils. Am J Surg Pathol, 1987; 11(2): p. 122–32.PubMed
Leblond, V., et al., Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol, 2001; 19(3): p. 772–8.PubMed
Dotti, G., et al., Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation, 2002; 74(8): p. 1095–102.PubMed
Dhir, R.K., M.A. Nalesnik, and A.J. Demetris, Latent membrane protein expression in posttransplant lymphoproliferative diseases. Appl Immunohistochem, 1995; 22(3): p. 299–309.
Finn, L., et al., Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol, 1998; 22(3): p. 299–309.PubMed
Delecluse, H.J., et al., Post-transplant lymphoproliferative disorders with genetic abnormalities commonly found in malignant tumours. Br J Haematol, 1995; 89(1): p. 90–7.PubMed
Gallego, M.S., et al., Trisomy 3 in two paediatric post-transplant lymphomas. Br J Haematol, 2002; 117(3): p. 558–62.PubMed
Poirel, H.A., A. Schneider, and M. Meddeb, Characteristic pattern of chromosomal gains and losses in posttransplant lymphoproliferative disorders (PTLDs): Correlation with EBV status and clincial outcome. Blood, 2002; 100(38): p. (abstr #133).
Knowles, D.M., et al., Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood, 1995; 85(2): p. 552–65.PubMed
Greiner, T.C., et al., Molecular epidemiology of EBNA-1 substrains of Epstein-Barr virus in posttransplant lymphoproliferative disorders which have infrequent p53 mutations. Leuk Lymphoma, 2000; 38(5–6): p. 563–76.PubMed
Cesarman, E., et al., BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood, 1998; 92(7): p. 2294–302.PubMed
Scheinfeld, A.G., et al., Epstein-Barr virus latent membrane protein-1 oncogene deletion in post-transplantation lymphoproliferative disorders. Am J Pathol, 1997; 151(3): p. 805–12.PubMed
Smir, B.N., et al., Molecular epidemiology of deletions and mutations of the latent membrane protein 1 oncogene of the Epstein-Barr virus in posttransplant lymphoproliferative disorders. Lab Invest, 1996; 76(3): p. 439.
Alizadeh, A.A., et al., Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000; 403(6769): p. 503–11.PubMed
Shipp, M.A., et al., Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med, 2002; 8(1): p. 68–74.PubMed
Greiner, T.C., A. Rosenwald, and M. Chiorazzi, Gene expression profiling by cDNA microarray in post-transplant lymphoproliferative disorders. 2004
Bhatia, S., et al., Malignant neoplasms following bone marrow transplantation. Blood, 1996; 87(9): p. 3633–9.PubMed
Curtis, R.E., et al., Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood, 1999; 94(7): p. 2208–16.PubMed
Socie, G., et al., New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia. J Clin Oncol, 2000; 18(2): p. 348–57.PubMed
Nash, R.A., et al., Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases. Biol Blood Marrow Transplant, 2003; 9(9): p. 583–91.PubMed
Powell, J.L., et al., An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant, 2004; 33(6): p. 651–7.PubMed
Cohen, J., Gandhi M, Naik P, Cubitt D, Rao K, Thaker U, Davies EG, Gaspar B, Amorlia PJ, Veys P, Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol, 2005; 129: p. 229–239.PubMed
Lucas, K.G., et al., Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood, 1998; 92(10): p. 3977–8.PubMed
Rooney, C.M., et al., Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 1998; 92(5): p. 1549–55.PubMed
van Esser, J.W., et al., Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 2001; 98(4): p. 972–8.PubMed
Rowe, D.T., et al., Epstein-Barr virus load monitoring: its role in the prevention and management of posttransplant lymphoproliferative disease. Transpl Infect Dis, 2001; 3(2): p. 79–87.PubMed
Kuehnle, I., et al., CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem cell transplantation. Blood, 2000; 95(4): p. 1502–5.PubMed
Tolar, J., Coad JE, Ramsay NKC, Peters C, Davies SM, Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation. Bone Marrow Transpl, 2001; 28: p. 808–810.
Milpied, N., et al., Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol, 2000; 11Suppl 1: p. 113–6.PubMed
Faye, A., et al., Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol, 2001; 115(1): p. 112–8.PubMed
Papadopoulos, E.B., et al., Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med, 1994; 330(17): p. 1185–91.PubMed
Bonini, C., et al., HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 1997; 276(5319): p. 1719–24.PubMed
Ho, M., et al., The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation, 1988; 45(4): p. 719–27.PubMed
Cox, K.L., et al., An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation, 1995; 59(4): p. 524–9.PubMed
Newell, K.A., et al., Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. Transplantation, 1996; 62(3): p. 370–5.PubMed
Opelz G., D.B., Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transpl, 2003; 4: p. 222–230.
Guthery, S.L., et al., Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment. Transplantation, 2003; 75(7): p. 987–93.PubMed
McDiarmid, S.V., et al., Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation, 1998; 66(12): p. 1604–11.PubMed
Kauffman, H., Cherikh WS, Cheng Y, Hanto DW, Kahan BD, Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with reduced incidence of de novo malignancies. Transplantation, 2005; 80: p. 883–889.PubMed
Birkeland, S., Hamilton-Dutoit S., Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se? Transplantation, 2003; 76: p. 984–8.PubMed
Hayashi, R.J., et al., Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol, 2001; 23(1): p. 14–8.PubMed
Dror, Y., et al., Lymphoproliferative disorders after organ transplantation in children. Transplantation, 1999; 67(7): p. 990–8.PubMed
Gross TG, B. J., Park J, Greiner TC, Hinrich SH, Kaufman S, Langnas A, McDonald R, Ryckman F, Shaw B, Sudan D, Lynch JC., Low dose chemotherapy for the treatment of refractory post-transplant lymphoproliferative disease in children. J Clin Oncol, 2005; 23: p. 6481–6488.PubMed
Buell JF, G. T., Hanaway MJ, Trofe J, Roy-Chaudhury P, First MR, Woodle ES, Post transplant lymphoproliferative disorder: Significance of central nervous system involvement. Transplant Proc, 2005; 37: p. 954–955.PubMed
Trofe J, B. J., Beebe TM, Hanaway MJ, First MR, Alloway RR, Gross TG Woodle ES, The Israel Penn International Transplant Tumor Registry 32 year Experience with 402 Renal Transplant Recipients with Post Transplant Lymphoproliferative Disease: Multivariate Analysis of Risk Factors that Influence Survival. Am J Transplant, 2005; 5: p. 775–780.PubMed
Paya C.V., F. J.J., Nalesnik M.A., Kieff E., Green M., Gores G., Habermann T.M., Wiesner R.H., Swinnen L.J., Woodle E.S., Bromberg J.S., Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. Transplantation, 1999; 68: p. 1517–1525.PubMed
Green M, M. M.G., Webber S.A., Rowe D, Reyes J, The management of Epstein-Barr virus associated posttransplant lymphoproliferative disorders in pediatric solid-organ transplant recipients. Pediatr Transpl, 1999; 3: p. 271–281.
Davis, C.L., The antiviral prophylaxis of post-transplant lymphoproliferative disease. Springer Semin Immunopathol, 1998; 20: p. 437–453.PubMed
Lee T.C., S. B., Rooney C.M., Heslop H.E., Gee A.P., Caldwell Y, Barshes N.R., Scott J.D., Bristow L.J., O’Mahony C.A., Goss J.A., Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transpl, 2005; 5: p. 2222–2228.
Ghobrial I.M., H. T.M., Ristow K.M., Ansell S.M., Macon W., Geyer S.M., McGregor C.G., Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymph, 2005; 46: p. 191–196.
smets F, L. D., Bazin H, Reding R, Otte J-B, Buts J-P, Sokal E.M., Ratio bewteen Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. Transplantation, 2002; 73: p. 1603–1610.PubMed
Savoldo B, R. C., Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, Finegold MJ, Dotti G, Heslop HE, Goss JA., Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant, 2005; 5: p. 566–72.PubMed
Starzl, T.E., et al., Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet, 1984; 1(8377): p. 583–7.PubMed
Aull, M.J., et al., MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation, 2003. 75(2): p. 225–8.PubMed
Mamzer-Bruneel M-F, L. C., Morelon E, et al, Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol, 2000; 18: p. 3622–3632.PubMed
Benkerrou M, J. J., Leblond V, et al, Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood, 1998; 92: p. 3137–3147.PubMed
Swinnen, L.J., M. LeBlanc, and Y. Kasamon, Phase II study of sequential reduction in immunosuppression, interferon alpha-2b, and ProMACE-CytaBOM chemotherapy for post-transplant lymphoproliferative disorder (PTLD) (SWOG/ECOGS9239). Blood, 2003; 102: p. 403a.
Swinnen, L.J., et al., Aggressive treatment for postcardiac transplant lymphoproliferation. Blood, 1995; 86(9): p. 3333–40.PubMed
Davis, C.L., et al., Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation, 1998; 66(12): p. 1770–9.PubMed
Liebowitz D, A. J., Hagos F, et al, Post-transplant lymphoproliferative disorders (PTLD): clinicopathologic characterization and response to immunomodulatory therapy with interferon-alpha. Ann Oncol, 1996; 7: p. 28 (abstr).
Shapiro RS, C. A., McGuire W, et al, Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin. N Engl J Med, 1988; 318: p. 1334 (letter).PubMed
Petit B, L. M.Y., Jaccard A, Paraf F, Leroux Robert C, Bordessoule D, Labrousse F, Drouet M, Influence of Host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation, 2002; 73: p. 265–271.PubMed
Emanuel, D.J., et al., Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation, 1997; 63(11): p. 1691–4.PubMed
Haque, T., et al., Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation, 2001; 72(8): p. 1399–402.PubMed
Sherritt, M.A., et al., Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy. Transplantation, 2003; 75(9): p. 1556–60.PubMed
Kaplan LD, L. J., Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT., Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005; 106: p. 1538–43.PubMed
Choquet S, H. R., Socie G, et al: Multicenter, open label, phase II trial to evaluate the efficacy and safety of treatment with rituximab in patients suffering from B-cell post transplantation lymphoproliferative disorders (BPTLD) (M39037 trial). Ann Oncol, 2002;13:p. 37 (abstr).
Haddad E, P. S., Leblond V, Seigneurin J-M, Sten M, Achkar A, Bauwens M, Delwali V, Debray D, Duvoux C, Hubert P, Hurault de Ligny B, Wijdenes J, Durandy A, Fischer A, Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1–2 clincal trial. Blood, 2001; 97: p. 1590–1597.PubMed
Buell JF, G. T., Hanaway MJ, Trofe J, Muthiak C, First RM Alloway RR, Woodle ES, Chemotherapy for PTLD: The Israel Penn International Transplant Tumor Registry Experience. Transplant Proc, 2005; 37: p. 956–957.PubMed
Orjuela, M., et al., A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res, 2003; 9(10 Pt 2): p. 3945S–52S.PubMed
World, H., Organization, et al., The world health report 2004: changing history., ed. Geneva. 2004; World Health Organization.
Aids Cases, Deaths, and Person Living with AIDS by year 1985. 2002; United States: Centers for Disease Control and Prevention.
Scadden, D.T., AIDS-related malignancies. Annu Rev Med, 2003; 54: p. 285–303.PubMed
Biggar, R.J., M. Frisch, and J.J. Goedert, Risk of cancer in children with AIDS. AIDS-Cancer Match Registry Study Group. Jama, 2000; 284(2): p. 205–9.PubMed
Rabkin, C.S., et al., Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. Jama, 1992; 267(8): p. 1090–4.PubMed
Mueller, B.U., HIV-associated malignancies in children. AIDS Patient Care STDS, 1999; 13(9): p. 527–33.PubMed
Levine, A.M., Acquired immunodeficiency syndrome-related lymphoma: clinical aspects. Semin Oncol, 2000; 27(4): p. 442–53.PubMed
Carbone, A., et al., Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas. Blood, 2001; 97(3): p. 744–51.PubMed
Boshoff, C. and R. Weiss, AIDS-related malignancies. Nat Rev Cancer, 2002; 2(5): p. 373–82.PubMed
Beral, V., et al., AIDS-associated non-Hodgkin lymphoma. Lancet, 1991; 337(8745): p. 805–9.PubMed
Levine, A.M., et al., Evolving characteristics of AIDS-related lymphoma. Blood, 2000; 96(13): p. 4084–90.PubMed
Levine, A.M., AIDS-related malignancies: the emerging epidemic. J Natl Cancer Inst, 1993; 85(17): p. 1382–97.PubMed
Caselli, D., et al., Human immunodeficiency virus-related cancer in children: incidence and treatment outcome — report of the Italian Register. J Clin Oncol, 2000; 18(22): p. 3854–61.PubMed
Pollock, B.H., et al., Risk factors for pediatric human immunodeficiency virus-related malignancy. Jama, 2003; 289(18): p. 2393–9.PubMed
Goedert, J.J., The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol, 2000; 27(4): p. 390–401.PubMed
Baumforth, K.R., et al., The Epstein-Barr virus and its association with human cancers. Mol Pathol, 1999; 52(6): p. 307–22.PubMed
Boman, F., H. Gultekin, and P.S. Dickman, Latent Epstein-Barr virus infection demonstrated in low-grade leiomyosarcomas of adults with acquired immunodeficiency syndrome, but not in adjacent Kaposi’s lesion or smooth muscle tumors in immunocompetent patients. Arch Pathol Lab Med, 1997; 121(8): p. 834–8.PubMed
Cesarman, E., et al., Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in AIDS-related bodycavity-based lymphomas. N Engl J Med, 1995; 332(18): p. 1186–91.PubMed
Chang, Y., et al., Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science, 1994; 266(5192): p. 1865–9.PubMed
Greene, M.H., T.I. Young, and W.H. Clark, Jr., Malignant melanoma in renal-transplant recipients. Lancet, 1981; 1(8231): p. 1196–9.PubMed
Kuhn, L., X.W. Sun, and T.C. Wright, Jr., Human immunodeficiency virus infection and female lower genital tract malignancy. Curr Opin Obstet Gynecol, 1999; 11(1): p. 35–9.PubMed
Shiramizu, B., B.G. Herndier, and M.S. McGrath, Identification of a common clonal human immunodeficiency virus integration site in human immunodeficiency virus-associated lymphomas. Cancer Res, 1994; 54(8): p. 2069–72.PubMed
Sparano, J.A., Human immunodeficiency virus associated lymphoma. Curr Opin Oncol, 2003; 15(5): p. 372–8.PubMed
Levine, A.M., AIDS-associated malignant lymphoma. Med Clin North Am, 1992; 76(1): p. 253–68.PubMed
Sanpakit, K., et al., Malignancies in HIV-infected children at Siriraj Hospital. J Med Assoc Thai, 2002; 85Suppl 2: p. S542–8.PubMed
Newton, R., et al., A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda. Int J Cancer, 2001; 92(5): p. 622–7.PubMed
McClain, K.L., et al., Molecular and virologic characteristics of lymphoid malignancies in children with AIDS. J Acquir Immune Defic Syndr, 2000; 23(2): p. 152–9.PubMed
Cabalo, E., et al., Molecular analysis and pathology of a second pediatric HIV-associated Burkitt lymphoma. Pediatr Pathol Mol Med, 2002; 21(6): p. 525–30.PubMed
Nador, R.G., et al., Human immunodeficiency virus (HIV)-associated polymorphic lymphoproliferative disorders. Am J Surg Pathol, 2003; 27(3): p. 293–302.PubMed
Gessain, A., et al., Human herpes virus 8 (Kaposi’s sarcoma herpes virus) and malignant lymphoproliferations in France: a molecular study of 250 cases including two AIDS-associated body cavity based lymphomas. Leukemia, 1997; 11(2): p. 266–72.PubMed
Jaffe, E.S., Primary body cavity-based AIDS-related lymphomas. Evolution of a new disease entity. Am J Clin Pathol, 1996; 105(2): p. 141–3.PubMed
Granovsky, M.O., et al., Cancer in human immunodeficiency virus-infected children: a case series from the Children’s Cancer Group and the National Cancer Institute. J Clin Oncol, 1998; 16(5): p. 1729–35.PubMed
Ambinder, R., Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer, 2001; 37: p. 152–9.
Tirelli, U., Bernardi D, Spina M, Vachher E, AIDS-related tumors: integrating antiviral and anticancer therapy. Crit Rev Oncol Hematol, 2002; 41: p. 299–315.PubMed
Dal, M., Franceschi S, Epidemiology of non-Hodgkin’s lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol, 2003; 4: p. 110–9.
Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst, 2000; 92(22): p. 1823–30.
Knowles, D., Pirog EC, Pathology of AIDS-related lymphomas and other AIDS-defining neoplasms. Eur J Cancer, 2001; 37: p. 1236–50.PubMed
Mueller, B.U., Cancers in children infected with the human immunodeficiency virus. Oncologist, 1999; 4(4): p. 309–17.PubMed
Kirk, O., Pederson C, Cozzi-Lepri A, et al., Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood, 2001; 98: p. 3406–12.PubMed
Mueller, B., Pizzo PA, Cancer in children with primary and secondary immunodeficiencies. J Pediatr, 1995; 126: p. 1–10.PubMed
Serraino, D. and S. Franceschi, Kaposi’s sarcoma and non-Hodgkin’s lymphomas in children and adolescents with AIDS. Aids, 1996; 10(6): p. 643–7.PubMed
Sandoval, C. and M. Swift, Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol, 1998; 31(6): p. 491–7.PubMed
Pinkerton, C., Hann I, Weston CL, et al., Immunodeficiency-related lymphoproliferative disorders: porspective data from the united Kingdom Children’s Cancer Study Group Registry. Br J Haematol, 2002; 118: p. 456–61.PubMed
Klein, U., Gloghini A, Gaidano G, Chadburn A, C. E, and D.-F. R, Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic derivation and identifies PEL-specific transcripts. Blood, 2003; 101: p. 4115–21.PubMed
Gaidano G, P.C., Lanza C, Mazza U, Saglio G, Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol, 1994; 69: p. 281–90.PubMed
Gaidano, G., Pastore C, Lanza C, Mazza U, Saglio G, Molecular pathology of AIDS-related lymphomas. Biologic aspects and clinicopathologic heterogeneity. Ann Hematol, 1994; 69: p. 281–90.PubMed
Antinori, A., et al., Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF. Neurology, 1997; 48(3): p. 687–94.PubMed
Auperin, I., et al., Primary central nervous system malignant non-Hodgkin’s lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers. Neuropathol Appl Neurobiol, 1994; 20(3): p. 243–52.PubMed
Meeker, T.C., et al., Evidence for molecular subtypes of HIV-associated lymphoma: division into peripheral monoclonal, polyclonal and central nervous system lymphoma. Aids, 1991; 5(6): p. 669–74.PubMed
Knowles, D., Pirog EC, Etiology and pathogenesis of AIDS-related non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am, 1996; 10: p. 1081–1109.PubMed
Bower, M. and K. Fife, Current issues in the biology of AIDS-related lymphoma. HIV Med, 2001; 2(3): p. 141–5.PubMed
Okano, M. and T.G. Gross, A review of Epstein-Barr virus infection in patients with immunodeficiency disorders. Am J Med Sci, 2000; 319(6): p. 392–6.PubMed
Ballerini, P., et al., Molecular pathogenesis of HIV-associated lymphomas. AIDS Res Hum Retroviruses, 1992; 8(5): p. 731–5.PubMed
Miller, G., The switch between latency and replication of Epstein-Barr virus. J Infect Dis, 1990; 161(5): p. 833–44.PubMed
Ng, V.L. and M.S. McGrath, The immunology of AIDS-associated lymphomas. Immunol Rev, 1998; 162: p. 293–8.PubMed
Pelicci, P.G., et al., Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med, 1986; 164(6): p. 2049–60.PubMed
De Re, V., et al., p53 protein over-expression and p53 gene abnormalities in HIV-1-related non-Hodgkin’s lymphomas. Int J Cancer, 1994; 56(5): p. 662–7.PubMed
Knowles, D.M., Molecular pathology of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphoma. Semin Diagn Pathol, 1997; 14(1): p. 67–82.PubMed
Nador, R.G., et al., Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood, 1996; 88(2): p. 645–56.PubMed
Nakamura, H., et al., Mutation and protein expression of p53 in acquired immunodeficiency syndrome-related lymphomas. Blood, 1993; 82(3): p. 920–6.PubMed
Martinez-Maza, O. and E.C. Breen, B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol, 2002; 14(5): p. 528–32.PubMed
Tarantul, V., et al., Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus-associated non-Hodgkin’s lymphoma. Neoplasia, 2001; 3(2): p. 132–42.PubMed
Delecluse, H.J., et al., Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern. J Pathol, 1999; 188(2): p. 133–8.PubMed
Davi, F., et al., Burkitt-like lymphomas in AIDS patients: characterization within a series of 103 human immunodeficiency virus-associated non-Hodgkin’s lymphomas. Burkitt’s Lymphoma Study Group. J Clin Oncol, 1998; 16(12): p. 3788–95.PubMed
Herndier, B.G., L.D. Kaplan, and M.S. McGrath, Pathogenesis of AIDS lymphomas. Aids, 1994; 8(8): p. 1025–49.PubMed
Grulich, A.E., et al., B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS. Aids, 2000; 14(2): p. 133–40.PubMed
Przybylski, G.K., et al., Evidence for early B-cell activation preceding the development of Epstein-Barr virus-negative acquired immunodeficiency syndrome-related lymphoma. Blood, 1996; 88(12): p. 4620–9.PubMed
Bessudo, A., et al., Favored use of immunoglobulin V(H)4 Genes in AIDS-associated B-cell lymphoma. Blood, 1996; 88(1): p. 252–60.PubMed
Muller, J.R., et al., Persistence of immunoglobulin heavy chain/c-myc recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sci U S A, 1995; 92(14): p. 6577–81.PubMed
Ng, V.L., et al., VH gene use by CD5+ AIDS-associated B-cell lymphoproliferations. Ann N Y Acad Sci, 1995; 764: p. 507–8.PubMed
Rodriguez-Alfageme, C., et al., B cells malignantly transformed by human immunodeficiency virus are polyclonal. Virology, 1998; 252(1): p. 34–8.PubMed
Ng, V., Hurt MH, Herndier BG, Fry KE, McGrath MS, VH gene use by HIV type 1-associated lymphoproliferations. AIDS Res Hum Retroviruses, 1997; 13: p. 135–49.PubMed
Preciado, M.V., et al., EBV-associated Hodgkin’s disease in an HIV-infected child presenting with a hemophagocytic syndrome. Leuk Lymphoma, 2001; 42(1–2): p. 231–4.PubMed
Preciado, M.V., et al., Epstein Barr virus-associated lymphoma in HIV-infected children. Pathol Res Pract, 2002; 198(5): p. 327–32.PubMed
Kaplan, L.D., et al., Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin’s lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med, 1997; 336(23): p. 1641–8.PubMed
Sandler, A.S. and L.D. Kaplan, Diagnosis and management of systemic non-Hodgkin’s lymphoma in HIV disease. Hematol Oncol Clin North Am, 1996; 10(5): p. 1111–24.PubMed
McClain, K.L., V.V. Joshi, and S.B. Murphy, Cancers in children with HIV infection. Hematol Oncol Clin North Am, 1996; 10(5): p. 1189–201.PubMed
Robinson, M.R., et al., Burkitt’s/Burkitt’s-like lymphoma presenting as bacterial sinusitis in two HIV-infected children. AIDS Patient Care STDS, 2001; 15(9): p. 453–8.PubMed
Errante, D., et al., Hodgkin’s disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol, 1999; 10(2): p. 189–95.PubMed
Levine, A.M., Hodgkin’s disease in the setting of human immunodeficiency virus infection. J Natl Cancer Inst Monogr, 1998; (23): p. 37–42.PubMed
Filipovich, A.H., et al., The Immunodeficiency Cancer Registry. A research resource. Am J Pediatr Hematol Oncol, 1987; 9(2): p. 183–4.PubMed
Morrell, D., E. Cromartie, and M. Swift, Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst, 1986; 77(1): p. 89–92.PubMed
Perry, G.S., 3rd, et al., The Wiskott-Aldrich syndrome in the United States and Canada (1892–1979). J Pediatr, 1980; 97(1): p. 72–8.PubMed
Seemayer, T.A., et al., X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res, 1995; 38(4): p. 471–8.PubMed
Sumegi, J., et al., Correlation of mutations of the SH2D1A gene and epstein-barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood, 2000; 96(9): p. 3118–25.PubMed
Robison, L.L., et al., Hodgkin’s disease in pediatric patients with naturally occurring immunodeficiency. Am J Pediatr Hematol Oncol, 1987; 9(2): p. 189–92.PubMed
Seidemann, K., et al., Therapy for non-Hodgkin lymphoma in children with primary immunodeficiency: analysis of 19 patients from the BFM trials. Med Pediatr Oncol, 1999; 33(6): p. 536–44.PubMed
Hoffmann, T., et al., Matched unrelated allogeneic bone marrow transplantation for recurrent malignant lymphoma in a patient with X-linked lymphoproliferative disease (XLP). Bone Marrow Transplant, 1998; 22(6): p. 603–4.PubMed
Fischer, A., Primary immunodeficiency diseases: an experimental model for molecular medicine. Lancet, 2001; 357(9271): p. 1863–9.PubMed
Villa, A., Santagata S, Bozzi F, et al, Partial V(D)J recombinationation activity leads to Omenn syndrome. Cell, 1998; 93: p. 885–896.PubMed
Ege, M., Ma Y, Manfras B, Kalwak K, Lu H, Lieber MR, Schwartz K, Pannicke U, Omenn syndrome due to ARTEMIS mutations. Blood, 2005; 105: p. 4179–4186.PubMed
Mustillo, P., Boyer M, Termuhlen A, Altura R, Klopfenstein K, Nicol K, Scherzer R, Gross T., EBV-negative, B-cell non-Hodgkin’s lymphoma (B-NHL) in X-linked severe combined immunodeficiency (X-SCID): remission with engraftment of donor T-cells. J Pediatr Hematol Oncol, 2005; 27: p. 466.
Derry, J.M., H.D. Ochs, and U. Francke, Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell, 1994; 79(5): p. following 922.
Coffey, A.J., et al., Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet, 1998; 20(2): p. 129–35.PubMed
Sayos, J., et al., The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature, 1998; 395(6701): p. 462–9.PubMed
Imashuku, S., et al., Requirement for etoposide in the treatment of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. J Clin Oncol, 2001; 19(10): p. 2665–73.PubMed
Gross, T.G., et al., Cure of X-linked lymphoproliferative disease (XLP) with allogeneic hematopoietic stem cell transplantation (HSCT): report from the XLP registry. Bone Marrow Transplant, 1996; 17(5): p. 741–4.PubMed
Lankester, A., Visser L, Bredius R, Van Tol M, Hartwig N, van der Burg M, Gross TG, Gaspar HB, Egeler M., Allogeneic stem cell transplantation in X-linked lymphoproliferative disease in different stages of disease: two cases in one family and review of the literature. Bone Marrow Transpl, 2005; 36: p. 99–105.
Barbosa, M.D., et al., Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature, 1996; 382(6588): p. 262–5.PubMed
Ward, D.M., S.L. Shiflett, and J. Kaplan, Chediak-Higashi syndrome: a clinical and molecular view of a rare lysosomal storage disorder. Curr Mol Med, 2002;2(5): p. 469–77.PubMed
Notarangelo, L.D., M. Duse, and A.G. Ugazio, Immunodeficiency with hyper-IgM (HIM). Immunodefic Rev, 1992; 3(2): p. 101–21.PubMed
Hayward, A.R., et al., Cholangiopathy and tumors of the pancreas, liver, and biliary tree in boys with X-linked immunodeficiency with hyper-IgM. J Immunol, 1997; 158(2): p. 977–83.PubMed
Rieux-Laucat, F., et al., Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 1995; 268(5215): p. 1347–9.PubMed
Sleight, B., Prasad VS, DeLaat C, Steele P, Ballard E, Arceci RJ, Sidman CL., Correction of autoimmune lymphoproliferative syndrome by bone marrow transplantation. Bone Marrow Transplant, 1998; 22: p. 375–80.PubMed
van der Werff Ten Bosch, J., et al., Reversion of autoimmune lymphoproliferative syndrome with an antimalarial drug: preliminary results of a clinical cohort study and molecular observations. Br J Haematol, 2002; 117(1): p. 176–88.PubMed
Shiloh, Y. and G. Rotman, Ataxia-telangiectasia and the ATM gene: linking neurodegeneration, immunodeficiency, and cancer to cell cycle checkpoints. J Clin Immunol, 1996; 16(5): p. 254–60.PubMed
Shiloh, Y., ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer, 2003; 3(3): p. 155–68.PubMed
Wong, K.K., et al., Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature, 2003; 421(6923): p. 643–8.PubMed
Hecht, F. and B.K. Hecht, Chromosome changes connect immunodeficiency and cancer in ataxia-telangiectasia. Am J Pediatr Hematol Oncol, 1987; 9(2): p. 185–8.PubMed
Giovannetti, A., et al., Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood, 2002; 100(12): p. 4082–9.PubMed
Gatti, R.A. and R.A. Good, Occurrence of malignancy in immunodeficiency diseases. A literature review. Cancer, 1971; 28(1): p. 89–98.PubMed
Gross TG: Infectious Mononucleosis and other EBV-related disorders. In: Wintrobe’s Clinical Hematology, 11th Ed., Eds JP Greer, J Foerster, JN Lukens, et al, 2004; Lippincott Williams and Wilkins, Philadelphia.
Gross TG, Shiramizu B. Lymphoproliferative disorders and malignancies related to immunodeficiencies. In: Principles an Practive of Pediatric Oncology 5th Ed., Eds PA Pizzo, DG Poplock, Lippincott Williams an Wilkins, Philadelphia, PA, 2005